Efficacy and Safety of Niraparib as First-Line Maintenance Treatment for Patients with Advanced Ovarian Cancer: Real-World Data from a Multicenter Study in China
Work
Year: 2023
Type: article
Abstract: Poly (ADP-ribose) polymerase (PARP) inhibitors are a new maintenance therapy option for patients with ovarian cancer (OC). To evaluate the efficacy and influencing factors of the novel PARP inhibitor ... more
Source: Targeted Oncology
Institutions Zhongda Hospital Southeast University, Obstetrics and Gynecology Hospital of Fudan University, Southeast University, Jiangsu Cancer Hospital, Nanjing Medical University +16 more
Cites: 30
Cited by: 11
Related to: 10
FWCI: 3.11
Citation percentile (by year/subfield): 79.75
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Sustainable Development Goal Good health and well-being
Open Access status: hybrid
APC paid (est): $4,390
Funders National Natural Science Foundation of China, Jiangsu Provincial Key Research and Development Program, National Key Research and Development Program of China
Grant IDS 82072078, SBE2020741118, 2022YFC2403400